Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab and Cemdisiran in PNH (ACCESS 2)
NCT05131204Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Antisense DNA, Recombinant Proteins and Enzymes, Conjugated siRNA
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing Pozelimab and Cemdisiran with Anti-C5 standard-of-care (2 arms). Primary endpoint: Percent Change in Lactate Dehydrogenase (LDH) at 36 weeks. Started Oct 2022; status: terminated.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05131204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131204.